{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16544257",
  "DateCompleted": {
    "Year": "2006",
    "Month": "08",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2006",
        "Month": "03",
        "Day": "13"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0022-1899",
      "JournalIssue": {
        "Volume": "193",
        "Issue": "8",
        "PubDate": {
          "Year": "2006",
          "Month": "Apr",
          "Day": "15"
        }
      },
      "Title": "The Journal of infectious diseases",
      "ISOAbbreviation": "J Infect Dis"
    },
    "ArticleTitle": "Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda.",
    "Pagination": {
      "StartPage": "1160",
      "EndPage": "1163",
      "MedlinePgn": "1160-3"
    },
    "Abstract": {
      "AbstractText": [
        "Malaria infections in Africa frequently include multiple parasite strains. We examined the relationship between the number of infecting Plasmodium falciparum strains and the responses to 3 different combination therapies in 3072 patients with uncomplicated malaria at 7 sites in Uganda. Patients infected with > or =3 strains had almost 3 times the odds of treatment failure (odds ratio, 2.93 [95% confidence interval, 2.51-3.43]; P<.001), compared with those infected with 1 or 2 strains. Our data suggest that efforts to reduce the complexity of infection in highly endemic areas through the use of intermittent presumptive therapy, improved case management, and reduction in transmission intensity may improve the efficacy of antimalarial therapies."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, USA."
          }
        ],
        "LastName": "Lee",
        "ForeName": "Sulggi A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Yeka",
        "ForeName": "Adoke",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nsobya",
        "ForeName": "Samuel L",
        "Initials": "SL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Dokomajilar",
        "ForeName": "Christian",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rosenthal",
        "ForeName": "Philip J",
        "Initials": "PJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Talisuna",
        "ForeName": "Ambrose",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Dorsey",
        "ForeName": "Grant",
        "Initials": "G"
      }
    ],
    "GrantList": [
      {
        "GrantID": "T32 AI060530",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Infect Dis",
    "NlmUniqueID": "0413675",
    "ISSNLinking": "0022-1899"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antimalarials"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Antimalarials"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child, Preschool"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Infant"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Malaria, Falciparum"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Odds Ratio"
    },
    {
      "QualifierName": [
        "classification",
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Plasmodium falciparum"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Uganda"
    }
  ]
}